TriangleBI 764532, dose 1 (NCT05882058)
BI 764532, dose 1 trial for Small Cell Lung Carcinoma (NCT05882058). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory small-cell lung cancer, lung large-cell neuroendocrine carcinoma, or extrapulmonary neuroendocrine carcinoma excluding Merkel-cell, medullary-thyroid, and neuroendocrine-prostate cancers. Prior platinum is required; small-cell lung cancer requires two prior lines.
The idea: infused obrixtamig connects DLL3-bearing tumor cells with CD3-bearing T cells. Part one compares two doses. Expansion cohorts require DLL3-high extrapulmonary disease and use one dose. Early visits include overnight safety monitoring. Researchers assess response and adverse effects.
This phase 2 study plans 204 patients. Boehringer Ingelheim sponsors; twelve US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.